Asian Growth Leaders With High Insider Ownership June 2026Simplywall·Jun 22 at 06:13 PM688275+1.02%300497+0.67%
The highest expected increase exceeds 32 times, nearly 90% of companies forecast positive results, and the A-share first quarter report has "opened with a bang."腾讯新闻 - 财经·Mar 29 at 07:39 PM688578-3.77%002082+4.92%
Innovative drug concept stocks continue to be strong, with Menovo hitting a 3-day consecutive limit up, followed by Fushine, BHC, Kingchem, APELOA, and WuXi AppTecWallstreetcn·Mar 25 at 08:35 PM510660+0.86%603538+3.04%
CRO concept stocks fluctuated and strengthened, with Fushine and Menovo both hitting the daily limit, Kingchem rising more than 10%, and Biocytogen, BHC, and ChemPartner following suitWallstreetcn·Mar 23 at 08:42 PM688796-1.51%300497+0.67%
A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suitZhitong·Nov 2, 2025 at 07:48 PM300878+10.34%300497+0.67%
Fushine: Net profit loss of 55.8404 million yuan in the third quarter, a decrease of 40.96%Zhitong·Oct 27, 2025 at 07:31 AM300497+0.67%
A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suitZhitong·Oct 19, 2025 at 09:42 PM300357+0.13%300255+3.53%
Fushine's subsidiary establishes Weiran Business Alliance (Shanghai) Food Technology Co., LtdZhitong·Sep 25, 2025 at 03:37 AM300497+0.67%
Innovative drug concept stocks surged and then fell back, with Mengke Pharmaceutical dropping over 10%, BrightGene, Bio-S falling over 7%, and YKYY, Konruns, EASTON BIOPHARMACEUTICALS, Fushine among those with the largest declinesZhitong·Sep 25, 2025 at 12:43 AM688166+3.49%301096+5.17%
Huachuang Securities: The commercialization of microbial protein is accelerating, suggesting to pay attention to ANGEL YEAST and FushineZhitong·Aug 31, 2025 at 09:16 PM600298+1.77%300497+0.67%
Fushine Pharmaceuticals released its performance for the first half of the year, with a net loss attributable to the parent company of 6.9112 million yuan, narrowing by 69.23%Zhitong·Aug 26, 2025 at 06:49 AM300497+0.67%
Innovative drugs and CRO concept stocks strengthen again, Sunshine Guojian Pharmaceutical rises over 10%Zhitong·May 26, 2025 at 09:00 PM002099+0.37%688336+3.61%
Fushine: Plans to develop multiple plant-based meat productsZhitong·May 25, 2025 at 05:50 AM300497+0.67%
Fushine: The microbial protein industry is still in its infancy in ChinaZhitong·May 21, 2025 at 07:53 PM300497+0.67%
